Longevity.Technology reviews key longevity developments and regulatory milestones of 2025

The longevity sector in 2025 was defined by the first FDA approval of a mitochondria-targeted therapy, growing economic arguments for healthspan-focused healthcare, and state-level legislative expansions of experimental medicine access.

Longevity.Technology published a retrospective of its 2025 editorial coverage, highlighting major structural, economic, and scientific shifts across the healthy aging sector.

In September 2025, the FDA approved Stealth BioTherapeutics' Forzinity, making it the first approved mitochondria-targeted therapy. Reenie McCarthy, CEO of Stealth BioTherapeutics, noted the implications of the decision for treating Barth syndrome and other diseases driven by impaired mitochondrial bioenergetics.

The McKinsey Health Institute released a report identifying seven 'shifts' to advance longevity biotech, calling for coalitions to run pivotal trials, global data collaboratives, and authoritative public-health frameworks.

Legislative shifts at the state level in the US, including models similar to Montana's, have expanded patient access to cell and regenerative therapies outside of standard FDA approval pathways.

The regulatory approval of Forzinity provides the first clinical and regulatory validation for targeting mitochondrial structure and function, which is a major hallmark of biological aging.

Geroscience is increasingly framed in macroeconomic terms, with researchers like Professor Andrea Maier emphasizing that governments are shifting to healthspan-focused frameworks to boost economic productivity and manage healthcare costs.

The decentralization of clinical access through expanded right-to-try laws indicates shifting patient and clinical demand, creating alternative routes for cell therapy commercialization.

The milestone regulatory approval of Forzinity is expected to reduce regulatory uncertainty for developers in the broader mitochondrial and bioenergetic space.

Calls from organizations like McKinsey for global data collaboratives and trial coalitions reflect a broader industry push to build shared infrastructure, which could lower clinical development barriers for early-stage longevity biotech companies.

The proliferation of clinics delivering novel therapies under relaxed state-level regulatory guidelines may expand clinical data collection, though it simultaneously raises the demand for standardized biological age clocks and validated biomarkers.

Regulatory developments surrounding state-level right-to-try expansions and potential pushback or guidance from the federal FDA.

Clinical advancement of other pipeline candidates focused on mitochondrial transplantation, quality control, and mitophagy as they navigate the post-Forzinity landscape.